REVIEW Open Access

# Choice of therapeutic interventions and outcomes for the treatment of infections caused by multidrug-resistant gramnegative pathogens: a systematic review



Sarah Melissa Nørgaard<sup>1†</sup>, Camilla Skaarup Jensen<sup>1†</sup>, Josefine Aalestrup<sup>1†</sup>, Christina M. J. E. Vandenbroucke-Grauls<sup>3</sup>, Mark G. J. de Boer<sup>2</sup> and Alma Becic Pedersen<sup>1\*</sup>

### **Abstract**

**Background:** Antimicrobial resistance is an increasingly serious threat to public health, and the increased occurrence of multidrug-resistant (MDR) bacteria is a concern in both high-income and low- and middle-income countries. The purpose of this systematic review was to identify and critically appraise current antimicrobial treatment options for infections with MDR Gram-negative bacteria.

**Methods:** A literature search for treatment of MDR extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae, *A. baumannii*, and *P. aeruginosa* was conducted in MEDLINE in January 2019. Relevant studies published in English, German, and French that evaluated clinical success, microbiological success, and 30-day mortality outcomes were included. The population of interest was adult patients.

**Results:** Of 672 studies, 43 met the inclusion criteria. Carbapenems are the most common antibiotics used for the treatment of ESBL-producing Enterobacteriaceae. The clinical and microbiological success was similar for group 1 carbapenems (imipenem, meropenem, or doripenem), group 2 carbapenems (ertapenem), and non-carbapenem antibiotics. Mortality data were contradictory for group 1 carbapenems compared to group 2 carbapenems. The most common treatment option for *A. baumannii* and *P. aeruginosa* infections was intravenous colistin, regardless of infection site. Clinical success and mortality were similar in *A. baumannii* infections treated with colistin combination therapy vs. colistin monotherapy, whereas heterogeneous results were found with respect to microbiological success. Monotherapy and colistin combination therapy were used against *P. aeruginosa* with clinical and microbiological success (70–100%) depending on the infection site and severity, and the antibiotic used. Ceftazidime-avibactam therapy for ESBL-producing Enterobacteriaceae and *P. aeruginosa* showed good clinical success in one study.

**Conclusion:** We did not find robust evidence for antibiotic treatment of any infection with MDR Gram-negative bacteria, including ESBL-producing Enterobacteriaceae, *A. baumannii*, and *P. aeruginosa*, that would lead to a firm recommendation for one specific antibiotic over another or for monotherapy over combination therapy. The choice of antibiotic treatment should be based on susceptibility testing balancing the expected clinical success rate against the risk of development of antibiotic resistance and the risk of severe side effects.

Keywords: A. baumannii, Enterobacteriaceae, MDR bacteria, P. aeruginosa, Review, Treatment

<sup>&</sup>lt;sup>1</sup>Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Allé 43-45, 8200 Aarhus, N, Denmark Full list of author information is available at the end of the article



<sup>\*</sup> Correspondence: abp@clin.au.dk

<sup>&</sup>lt;sup>†</sup>Sarah Melissa Nørgaard, Camilla Skaarup Jensen and Josefine Aalestrup contributed equally to this work.

### **Background**

Multidrug-resistant (MDR) infections constitute a serious public health problem [1] because they are difficult to treat effectively, leading to longer hospital stays, treatment failure, and adverse outcomes, such as complications and death [2, 3]. During the last few decades, several bacterial pathogens have evolved into MDR forms [1, 4]; of particular concern are MDR Gram-negative pathogens, such as Enterobacteriaceae, Acinetobacter spp., and Pseudomonas aeruginosa [5], which are becoming resistant to almost all available antibiotics [6]. Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae are responsible for a variety of community-onset and healthcare-associated infections and are associated with poor clinical outcomes [7, 8]. Acinetobacter baumannii can cause a variety of infections, including pneumonia and bloodstream infections, which are associated with high mortality and morbidity [9, 10]. P. aeruginosa is one of the main causes of serious nosocomial infections in Europe, including pneumonia, bloodstream infections, and urinary tract infections [11]. Other MDR Gram-negative bacteria are emerging, but are still rare and not a focus of the current review.

The European Centre for Disease Prevention and Control estimated in 2019 that infections caused by a subset of resistant bacteria are responsible for approximately 33,000 deaths in Europe annually [12]. The overall crude economic burden of antibiotic resistance in Europe has been estimated to be at least 900 million Euro in health care costs and 600 million Euros a year in lost productivity [4, 13]. Despite the increased occurrence of MDR organisms, data on which antimicrobial treatment with a single antibiotic or a combination of two or more are scarce [14]. The available guidelines from the USA and Australia are based on data up to 2015, which may already be obsolete because of the expanding evolution of MDR Gram-negative bacteria. European guidelines mostly focus on preventative measures thought to reduce the occurrence of MDR Gram-negative bacteria [5, 15–20]. Previous systematic reviews were based on heterogeneous studies with small, diverse populations from single centers, comparing various antimicrobial treatment options, and providing different results.

The aim of this systematic review was to evaluate how different antimicrobial treatments used in adult patients against MDR infections, focusing on ESBL-producing Enterobacteriaceae, *A. baumannii*, and *P. aeruginosa*, affect clinical success and mortality outcomes.

### **Methods**

The review protocol was not registered with the international prospective register of systematic reviews.

### Eligibility criteria

Eligible study designs included randomized clinical trials, observational studies, prospective or retrospective design,

concomitant or historical control studies, meta-analyses, and systematic reviews. Studies investigating any antimicrobial treatment for infections caused by MDR Gramnegative bacteria (ESBL-producing Enterobacteriaceae, *A. baumannii*, and *P. aeruginosa*) were included.

The population of interest was adult patients (age 18 years or older) who had a confirmed MDR infection and received antimicrobial treatment. We included studies that evaluated the outcomes of specific MDR Gramnegative bacteria with regard to the administered antimicrobial treatment. Studies directly comparing outcomes following different antibiotic treatments were of particular interest. However, we also included studies reporting the outcomes of specific treatments without a comparison treatment group.

The primary outcome of interest was clinical success from initiation of treatment until discharge or death. Clinical success was defined as complete resolution or substantial improvement of the signs and symptoms of the index infection, such that no further antibacterial therapy was necessary. Secondary outcomes were mortality, regardless of follow-up time after infection, or initiation of treatment and microbiological success measured by microbiological response, suppression, or eradication, bacteriological count, and laboratory outcome.

Studies published between January 1, 2006, and January 18, 2019, were included. For further details, please see the PICOS table (Additional file 1).

### Information source

MEDLINE was searched via the PubMed electronic database under the guidance of a research librarian for articles, and the reference lists of the included articles were reviewed to find additional articles.

# Literature search

Our search strategy included the following search terms: "multidrug resistant" AND "gram negative bacteria" AND "ESBL" OR "A. baumannii" OR "P. aeruginosa" (Additional file 2). We limited our search to the English, German, and French languages and studies in adult patients (≥18 years). The search terms covered the title and abstract of the paper. We included studies with any method of diagnosing MDR infection and any antimicrobial treatment. Many definitions have been used to characterize MDR infection, and most articles were not clear about the definition. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) defines MDR as acquired non-susceptibility to at least one agent in three or more antimicrobial categories [21]. If the authors classified infection as MDR, then the article was eligible for review, as we can only assume the EUCAST definition was applied. Any site of infection was included, including the respiratory tract, bloodstream, and urinary tract. Studies were selected through a threestage selection process described below. Additional articles were identified by checking the references of the already selected papers.

### Study selection

Our initial search targeted articles that 1) evaluated infections with MDR ESBL Enterobacteriaceae, A. baumannii, or P. aeruginosa, 2) mentioned a potential antimicrobial treatment, and 3) included information on the outcome of treatment. First, a literature search was performed independently by three reviewing authors (SMN, CSJ, and JA), selecting relevant papers with the aforementioned MDR Gram-negative bacteria included in the title. Second, abstracts were reviewed by three reviewing authors for the other two eligibility criteria (administered antimicrobial treatment and outcome of interest). Due to different nomenclature for MDR, after consulting with the senior tiebreaking author (ABP), we decided to include different synonyms (e.g., carbapenem resistance and extremely drug-resistant) in the study selection process to insure inclusion of all articles concerning MDR bacteria. At the third stage, the full-text versions of potentially eligible publications were obtained and distributed evenly between the three reviewing authors and examined in detail according to a predefined extraction form (Tables 1, 2 and 3). Standardized, pre-determined, study criteria were applied to all full-text documents.

At each stage, disagreements about the fulfilment of eligibility criteria were resolved by consensus or in consultation with the senior tie-breaking author. Search results were exported to EndNote V.X7.4 (Thomson Reuters, New York, New York, United States) and duplicates removed. The EndNote database with full-text articles is available upon request. The selection process is presented in Fig. 1.

# Data extraction and assessment of study quality

Data were extracted using a structured and standardized form piloted in six studies (Tables 1, 2 and 3). Discrepancies were compared to the original data. Information was extracted on the following characteristics: author names, year of publication, country of origin, study design, study period, characteristics of the study population (size, age, inclusion criteria, and site of infection), follow-up time, antimicrobial treatment and administration, outcome evaluated, factors for which the analysis was adjusted, statistical analyses, and risk estimates with pvalues. Each review author presented extracted data for discussion with the other two review authors. If a review author had any doubt regarding extracted data, the paper was reviewed by another review author and disagreements resolved by discussion between the two review authors or in consultation with the senior author.

**Table 1** Choice of treatment and outcomes for ESBL-producing *Enterobacteriaceae* 

							SBL-predu	ing Enterob	olmisces							_
down	Needy Equir	Publicati	Nuty	facility	Indetentriote	No. of	Study class	neterklies Artebrolid	Krair	Faller	Xlord	Outcome	Owier	Boulo	Faten	Study quality Onde
horald	Residence of second and second an	an year and country of religion 2011 Elemen	303 367	*	Relatives individual with a behildren exercision of the control of	To the state of th	Montage (passed) MCI 12/040 and MCI	Procedition to the control of the co	16.	200	UN UN	Check house, and the check of section 20 kg models of	Means and a state of the state	Chind course 1723 Mr. Enganes Ni. Enganes Ni. (1998) The Chind Chind P.2 Mr. Enganes Ni. (1998) The Chind P.2 Mr. (1998) The Chind P.2 Mr. (1998) The Chind Chind Chind P.2 Mr. (1998) The Chind Chind P.2 Mr. (1998) The Chind Chind P.2 Mr. (1998) The Chind Chind Chind Chind Chind (1998) The Chind Chind (1998) The Chind (1998) The Chind (1998) The Chind Chind (1998) The Chind (1998) Th	Finders reported to Management of the Management	-
Yeard	Resignative Magnetized study	30cT Boxis	900 200		Prices with some outhershifts count for Personalite Louisian managed by 15 Mar oil and transfer and transf	150	Ta per-74	Paracilla- teritorias Engenes	EV.	N Registre on of 70 days	VII	Newpirel stretchin Wanderbasi sel secure	Moder Critics	Managhti moristic PTD, 4% Erasona 1.7% [p.m.80] War-shaladed serves PTD, 90% (repose 19% (pr.1.80)	Length of boried star below MPS man. barrenters; 1975, wells dock man dock	Fic
Balance of	Resistance assertional assertional assertional assertional assertional assertional assertion ass	200 Theliani	368- 364	R	Binetialized estimo, III vars or sider unit o decument (150) c. de	10	4480190	Gross 2 cathogoness group 1 cathogoness	TV .	26 diga	UE Alexen 86	Chical warra Ministrating Scholar 20-bs metality	Media ir relar	Claim server. Discussions good Net. See Secusions good Net. See Secusions good Net. See Secusions good Net. See Secusions good 1 Net. Secusions good 1 Net	Six of infrastrum	Par
nago s	Residence, plant ET absoluted	200	2		Print with resoluted attach seem from the factor was the factor or contributed debended indicator cased by 1500.  Elementarionists was a factor of the facto	150	NORTH and ROPES	CET Continues of the co	rv.	d CR S P dan state 3 G S danc	ACRE addresses of	Clinical money. Whateholders and moures	Mudel e velor	Micro medially (Newsonial Section of the Newsonial Section of the Newso	Non	Tie:
Cardinos - Microsol de Cardinos de Cardino	Recognitive odel (see ) odel (see) policy (see ) odel	200 Spoh	260	*	were to the mostly against a gain of the g	766	Emphasia Scotty John St. Than St. St. Than St.	1 m	R	Nép	BK.	Chinal Control of the	06 92	Chiefe Amount Chiefe Common Pitte Common Common Pitte Common Comm	Empirical Engine Service Control of the Control of	Fac
the series	properties, spin-sibil, see spin-sibil planning spin-string)	3047 8169	200	KW	Adult prices with signs of N off symptoms within 7 days of mealering continue meaned and selections in district a factor of patients of the continue of the co	20	6935	Enques	EV.	\$ 15 pm	Aires	Claims record Mandrologi of Name	Modu Critico	Chinat secon Sit. Marshalephol secon 70.	Nex	ric .
Overboan of all	Estimate (in a chart study (deservational)	200 Bolgism	200	KW	problem gram logar or forcers.  Consults of parami- natural exhibition.  Elements are and around exhibition.  Simultonian exhibition of Signific at a safetypeom * 12 food.	٠	MAGNETS and 44201140	Critisins or Cartegorium	PV.	A manimum or a COP Alice	Allega abbasis of BK	Chincal masses Milandisclosed and mounts 30-300 mortality rate	Model critical	Clinkel resions Chinese sense. (20). Calegores peop. (6). (6+2-7). Waveletindend. (6)(6): 146. Calegores. 25). Le-0-70. Resional (25). Columna (26). Calegores. 26/. Calegores. 26/.	You	Par
Karajion al	Recognitive structural study	State Present	360 363		Patients indicated with 1550C, Enterodos between who was between the patients	×	Netwo	Dinks	W	M depa	USI 06 divorsi distante di	Claims secret Monthship of econs	Mode crelen	(price) Clinini server 1 de Odor sp. NS. H des Odor sp. 200. Wassistersp. at server 200. Wassistersp. at server	New (New Agents and Ag	-
Shoot of	Presenting descriptional study.	300 Ones	360 366 363 363		Painters with hadronisms also in 10th conditions also in 10th conditions of a color had been consistent to the color of a color hadron of a color of a col	50.000	903	Collection or improve	748.	N den N den	and the same of th	Chical money Membry	Media e ratio	Clinical control of the control of t	New	Good
Tables g at	Remaparity Startational study	261, 366y	341	*	Professor (18 years with distribution professor with this processor or appropriate processor and the processor of the processor of the processor of the pro- ting of the pro- ti	*	54015	Nederman	En.	A marine H of H dept	UN.	Claimi recore Shankedays of severe	Moder c refer	Clinical sources 10%. Microbiological sources 10%.	New	Ter
ipitatisi al	Kernepoline disensional analy	361. Dates	361	8	Adult patients 118 years, premiting with an heavance of the topold congruence, which is to the topold congruence, and the topold congruence, and the topold congruence, and topold congruence, and topold congruence, and the topological congruence, and the topolog	3	20 12 6+ 100	Andan	M	Tree colors and the colors of	OH.	Checal services in the control of second of second or control or control of second or control	Shedar a relar	Clinind research (%) Winterlengtod moreon of a location and of location (%) SH does the location of PE,	New	Ter
tord of (SKI)	Kernesotro dransfered wally	345. Talesm	836		Palando with dismidits destributed in destributed in the contributed in the contributed in the contributed of the first indication of \$1.000. In conduct of the contributed of the contributed for some such as relative for many such as relative for more such as relative for more first 40% to an included of a stributed of	4.	*	Citizen III askapanen	PV .	A manimum at al Citi digit	9	Note only mends	ce	30-des seule meralier 08/31/05/03/1 33/3 3-0300	Umageto, Fill habrerela user (A. Right) deal solicitist dease. Bellaster desep with critiques	Fee
Livid	Keresenine solver stub (discretisal)	2011. Existen	361		hideln are '15 ward with 1905 conductor for the	38	×	Homestake in criterios	TV .	A marine studios des	TR.	No.	Months or relies	NHO modeling (St. III) (St. IIII) (St. IIIII) (St. IIIII) (St. IIIIII) (St. IIIIIII) (St. IIIIIIIIII) (St. IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	Hearth court havenning governors, governors, groups, court fairly followed above the havenning across a port of a po	Fer-
Count of COLU	Kerementina structured study	261. Taleum	360 36f	н	Adultra and J. Ch. sand with 1985, resolution for fur-inflar audion Alaborate processing Participation and the subspaces in terms as processor for a four 12.5	24	m20116 and classics	Interest serveres empoun	78.	3 mains m (C)0 dex	18	Noberondo mondo	Meshal a reliar	Nein web sortalis inspense removes to the frinceson 14th (p=1,0)	New	Par
Const.id (SRC)	Retropodicy stray rational study	Yéwa.	200		management for a least 12 h.  Adulte 1 B years with 1200 conductor E. and 1200 conductor E. and 1200 conductor the second sub-		6(40)356 and 301 (1602)	Agergeine denser with references** of magnitudes denser with cartegenome	rv	Cod market ma market ma market ma ma ma ma ma ma ma ma ma ma ma ma ma	16	Sport school monolity	Modul s relean	Super-control mortality Assertation formers (a) (a) (a) (b) (a) (b) (b) (b) (b) (b) (b) (b) (b) (b) (b	Newton septi. Security and Security and Security for Secu	Fac
Officer	Retirements solven state (descriptions)	34T EXV	300		Midd EUP rosteddi misses with EUR; producing for foreign orit medicinalis processing EX.	129394	630360	Expected document value group is an in- company of the company of	N	S maximum or all You door	10	to consist metaline sociality metaling	CK.	Be-brashd moralis Charge (Comp.) Charge (Comp.) Charge (Comp.) College (Comp.) College (Comp.) (Comp.) (Comp.) (Comp.) (Comp.) (Comp.) (Comp.) (Comp.) (Comp.) (Comp.) (Comp.) (Comp.) (Comp.)	A Despital montality, NO day manufact, NO day manufact, Sociality facilities of district attention and LOS, medium 1,000 from cather, to day facilities of day facilities of day facilities of day facilities of the day of	Tec
Constitu	Endmind (Intel)	Sec., Noticed Including Int contribution	365		Pelatron ageil E-Wi SIGN VIO-Gooding complexed TT in principlinis on stall complexed TT in principlinis on stall control Tomory segment endockine principlinis on stall control Tomory segment endockine principlinis on stall in the stall of the stall principlinis of the stall control to stall principlinis was required when the stall to stall or stall of the stall was required when the stall was required when the stall was required when the stall principles of the stall was required when the stall principles of the stall was required when the stall principles of the stall principles of the stall principles of the stall principles of the stall principles of the stall stall principles of the stall principles of the stall principles of the stall stall principles of the stall principl	24.330	643 0-140 140 163 173 173 174 174 174 174 174 174 174 174 174 174	orbidine irboxen EXO THE IRC	W	POC risk N If days in dealers of readers a days days a d a days a d a days a d a a d a a d a d a d a a d a a d a d a a d a a a d a	92	Claimi (6009) Michighing and mounts	Moder Critis	Clinical sectors in USE CARTY BET-1915 BET-1915 BET-1915 BET-1915 BET-1915 BET-1915 BET-1915 BET-1915 BET-1915	No.	Par

Table 2 Choice of treatment and outcomes for A. baumannii

							Asins Neely sh	eductor Joseph anador bilan	menti							Med qui
Assets	Newly Injur	1	11	Summer	haban dark	As at periods (to treft)	2	Antonio talkal Strational	Ren	Taken.	No. of	rature	÷	Brain.	Tana reports Vity alpendo	the state of
Marine d	Anaparia Anaratisal casa and	10	361	800	Add power-death of a first control angular control angular control for loca file. If	-		1000	*	Maga Wald Wald	Artico	700 p. 20 (000 (000 (000)	Muser 1 teles	Principle and member 100	Anna Salbary Salbary Salbary	Face
					in the CC could requiring extension and about the control of the term that it bearing a strong a basiness college of males Accounted males and the college of the college o											
those of the state	Monapolite described risks	200	30		Patients who bell assessments as Indianastronic or architecture of the Control of	10	303	Stockers hand on designation of the gard of the face of the C. Burk-Villa	×	A mainte mainte de	Acres 186	Charle Marchalan Standard Alexand Jan Marchalan Marchalan Marchalan	Almahi 1 tihe	Charleson Star / St. Star / St. Star / St.	New	Box
					he the shadesheed and you			Buttered				north)		manager may/and may/and		
														Printers STATE STATE		
Vinue #	Amounts storated out;	Self. Fater	367	100	Palent Emmed with Y-10 occ s 1000 in CSB of temperal and development within temperal		38158158	Colonia Colonia Colonia		mention mention mention decr	Anne	Cheed maps Mandedoo d soon Chee matchs	( vsks	(a-6.6) Chindrama China	Constitute, direct masses (AFC as) descent reduce	Fee
							11 113							Carles and		
		! 		i	! 	! 				! 	! 			CARL CARL CARLESTON ECON	l	! 
Tripogle Lind	Policinos man Admir medicinal	Strate of	361		Objected while age Drawn tile designed CEA Systemicological	**	100 mm	Colore Colores	2	mind maked sometimes date after after	All	Charles Street, American American Security Security	Standar 1 tillar	Chickman Chickman C Chic Court No. Services	No	Rox
					nd square to most		1-16.9			ides research		Sec. in models		Cities (Carto		
														Manager Street China Short		
litera control of all	America described referred;	304. See:	364		Parlament with information countries for it. Insurances, reason and for its insurances of the section of the se	141	ŝ		×x		м	XMm of dear manufacture Modern		Principles medicale (ris postular) formation (b) (s) (ris) (s) (s) (ris) (s) (s) (ris)	Tables Children controller controller control control control control control	Fee
					sative in electric of land Primare. Información closed desenvalor delectron.			2000 1100 1100 1100 1100 1100 1100 1100						Printed Communication of the C	Talana Talana	
Street or	Acrescents	304. Paties	300		Patient - No. will a	200						190	Almoster 4 Kilon	Marian Maria	Ass. brooks	Ter.
	Amounts married may	Father	100		Patients - Hr. with a senderstand to the a framework factor of filled a framework factor of the angle of the angle of the angle of angle of the angl		324	Colors Colors colorses desperie desperie desperie desperie desperie desperie		201 801 751 Comb NO 0		1 Nov const Clean more Manufacture of secons	4 cabo	Prince and all teaching to the Common of the	NO. 5 to 1 Section of the control of	
					nendran r odni Keni enhancima termenti tr (1 km)			-						Martinger Season St. Season Martinger Marting Martinger Marting Marting Marting Marting Marting Marting Ma	Ann broaded ann product ASRL II Assessment ASRL IX man prior 1-7/CM A Assessment ASRL IX man prior 1-7/CM A Assessment ASRL IX man assessment ASRL IX man assessment as	
book	Section	100			NANAMA CEL	rm.	mate	000			Armer No.	Mandaday Estate	-Count	Statement Statem	Today Carlor	Two
Acces to	china tue	her			manushi mutange entereda til- ma mg soomal alamagan Oli			- Charge and - Cha		marine marine dec	16.	Manager of traces and the same same same same same same same sam	1180	1 17. (X) 17. (X) 17.	conceptions represent statement administration (Gap, procession	
					A bostonial							mende		7-12-0-0-0 	COMMENTS OF THE PARTY OF T	
	Rederinal				None and I to		M.C.M.	tones	11.00		AGE.	100W	- Charles	blockerded school 0.27s (ac. 17s (rel.26)	200	Two
	nati	Tarker	312		reproved a dispersion of the Publisher and and a state of the state of			ration observed	15	dates de bey		Manual Ma Manual Manual Manual Ma Manual Ma Ma Manual Ma Ma Ma Ma Ma Ma	s value	Plant who C. Ch. Sec. 15. Sec. 16. Sec. 16. Manual sec.		
					retired a figuration of the control									27.00 20.00 p. 100		
Tarijo a	Part I are	25.	2		Steen.	10	75.4 71.000 pag	Sporter	2	1881	200	Chard states Marchelan Factors	Allendar 1 Fabr	Chindren Translati (Chindren	New	Fee
	pen anne				forthe other of a fine August of policy action or susceptible or reproduce, without primorates a soluble		754 01000 as 250 2400 as 363 2400			Auc	-	# senior		Mindeleged Charles Co.		
					Antended of second and second and second and second and condition for flowy											
3000	Avenue of the last	100	13	100	Palacio Alfo, sociali articolori ai colorgia processidadi ai fondacioni		362	Bilanana Ingeses	2	50	Ano	Charle Charle Charle Charles	Product Franke	Change areas (r) Create areastre (r)	New	Fer
Name of Street	Objectional	John Market	304	100	To promove a basines of the control	э	CN + R/R	Calcala obseques	-	10	700	Chest	140	Chind-ware sen.	hou	Fee
					Secretarios procesos and a secretarios and addinguals solving radiography, below reason of A. Sonography				- in-							
Superior and (SM)	Rankerood Securities color stalp	200	Loge presid	100		24	40.00 21.00	Orbital amplified anhance	2	Tobar sike	April	Check	America 1 traffer	Chindren Links Mr. Lands M	New	Dia.
Cont					All medianed socialization (17) based with all medianed with all medianed based base			- Alexander		100		Chand series beneficial a series 1 hole series (Const.) de series				
														Microsoppi microsoppi constitute on D-101 Microsoppi constitute on American on American on		
														Management Co. Co. Strategy Co. Strategy Co. Control Co. Strategy Co.		
Travelar old (SIM)	Raderical property tod	304	200	100	Africanion socialists for 15 feature with position tipe 5 feature with position tipe 6 feature for 1	ъ	rian sila	American orbitals for play opinion orbital 2 11 play	×x	Foliate Laboration	A.	Chead	Almoster 4 miles	Children Out 175 One V 176	New	Fee
					manus de A			A STATE OF THE PARTY OF THE PAR		ed a ned a near to near to		Hilli		Charles of the Control of the Contro		
														Ower Pints Ower Pints Ower Pints proof		
														Company of the Company of the Compan		
														prompt prompt manufacture manufacture manufacture manufacture manufacture manufacture prompt prom prompt prom prom prom prom prom prom prom prom		
20.00	Armporte	an c	700	100	Address (1)	10	Septemb	Sporter			Artic	Owe	distant	Ome P 70 FAG (F-00)	Free	Fair
	and a	Louis	364		mental six mental specifies manual for passessmenting MOLA forgonial					÷		35	i edu	No.	French gards, alexander drooms, alexander contractor contractor totales french properties	
															Tributer province of the control of	
Xwed	Nonecotte.	20 th Balan	300	100	MANAGEM EST	54	THE	Tarolin	n		Aprel	Ond	America a color	Chindrens Species 4% Crises 40;	Territorio Territorio	Fee
	American male				processor and back- continued department beginning as NAO consecution of NAO consecution and A foresterning and A second other back-size as printed		e100	Tarantee white		÷		Marriedan Facility 1924 metally	11180	Monthless of Control o	Stell prom- ment (Ameliana), orthodoxy, orthodoxy, stellar, stella	
					transfer a pilote men a perfector ferror and a read a perfect of the first manufacture of the first									Make worldly Facus for SN Colors SN	Assessed Sections security	
ora	Amounts deposited skiy	30 th	30		Add below has 1 fined official and other below to SCAL below		1000	Minorita Manufacta Malatin Militar Mil	к		^**	Charles Marchalles Marchalles Marchalles	dissilar c volu	Chicat areas Security 1974 Security 1974	Nov	no.
					agents of a color of agents of a color of a			Francis September September September						North Str.		
					ethnocide oid observior star absentiary ethn 17 have at the cond at the condition of the condition of all assentiary of all assentiary for the											
	Postulina	Acres Storage	30		of accounting for 140 bases		STATE	**************************************	0	Russ	80	****	Audi	-	Personne	test
	deposited thely	Torus	30		A framework operation of the property of the p		end or	(wateren		reference makes to make to make makes destroy of		Common or Common	n-stee	mendin (* 1 th) (* 1 th) (* 1 th) (* 1 th) (* 1 th) (* 1 th) (* 1 th)	non, 307.6 non destr non, non, special special special	
					or cohappens which all beauty soften some their during speeds of becomes transmission									All pends broken service (A) 40% (a) 50% (a) 50%	Total Control of the	
Toward.	Material States where states other states	ye y benefits of freeze	201	100	Additions of the control of CRI - CR	(34	500m 20 3150	Other	2		Advago	New years	All models or relieve	Note monthly	SERVICE SERVIC	Const
Military do e a	Property and a second s	Z	22	100	MRX paper she manufactured and manufactured and and and and and	-	304043	one	Scholster	End Students 1 to Australia	April	Aller of largest months	Allenda) erallen	Alternative template manufact	Non	No.
that d a	Amusers deposited	mi.	267		Service and a se		81A10 61040	Pi school	TTUM		Ann	Manchings of self-denied mining	muse	Number of an extension of the second of the	N.W	Fac
	Annual and	Theised	30		Participation of exchaption of lambdate for the COM		4100	Parker:	17.00	reserve to set of tomore	111	37	ATTACANA TO AND ADDRESS OF THE PARTY OF THE	Produce Str. Produce Str. Produce Str. S-C-401		
														br-6401  Monamento Production Pro		
														Production Production Production (DEVENIEND		
														Address of 1900 Years of 1800 Years 1800 1800 Prints		
Questial	Personative colored study	822	22		Insulate horizo with conferred U.A.P shares XIII All without other basered infection.	e	90-09 103 1034	70-075 75	,	- No.	Arres	Charle	Almanda)	John J.	los ses teratolos er dess mineral	Fen
					harmful infenters									-	This was broaded and desirable	
															Minima Minima Minima MI	L
nogo s	Specialist project and activated parametrical	Serv. Dation	Sec	ľ	Status exclusive for efficient and solve-of-the following-politorie resiscent solveion facusalism.	20	No.	Others September Selection Money production Money		××	Air	Philadeless minimized		Chindren COD Con COD EXT.173.00 2.001	Sea	Const
					following antibinity systems: artists: a state of the antibinity of the antibinity of the antibinity of the antibinities of th									ERLEIDAS		
					contribution of mink shares for escales MCM, MCM or produces A franchistoria and con-									RELIGION .		
														Montenaged Seek Continued C EX1212.04 1341		
		i i	1	l												
														EXTENSION OF THE PARTY OF THE P		
A.M. acquire	anciva - canalos. Si consecuente de la compresio la compresiona del compr	al redshire	Service of	Makeyanan Makeyanan Makeyanan	listin, M annepresi et. 1961 - inhelistinte spellen, AAH - lind ( XYSY - landout shir die sannesten constitution ding	B = housing solitor, F = s dust Austr Pt	aning CO - Is since it is again solder it -	emin servel A other B 1 Marc 0.475 - San	III - counts	Colony notes believes to the	ecitalina or Maliago Rodal Erob	dan musah N F - Mapai Sinil, KSA -	promote promot	EXTLANT S.D.  Let 1  Combination  To 2  EXTLANT S.D.	and the country of a secondary	industry integral

Quality and risk of bias in individual studies were assessed at the study and outcome level jointly by all reviewing authors using the Study Quality Assessment Tool from The National Heart, Lung, and Blood Institute [22]. The results of the quality assessment are presented in Tables 1, 2 and 3. Each study was quality rated according to one of the following categories based on the proportion of yes answers to all relevant questions: poor quality, 0–40%; fair quality, 41–80%; and good quality, 81–100% [22]. Quality assessments were conducted by the three authors jointly. Disagreements about the quality assessment were resolved by consensus or in consultation with the senior author.

### **Summary measures**

The following measures of treatment success were included: absolute values, absolute risk differences, hazard ratio (HR), relative risk, and odds ratio. Unadjusted and adjusted measures were included if available.

### Planned methods of analyses

The investigators considered quantifying effect measures in a weighted formal meta-analysis if there were consistency in the study designs, participants, antimicrobial treatment, and reported outcome measures. Otherwise, the systematic review would focus on describing the studies, their results, their applicability, and their limitations, and a qualitative synthesis of the results rather than a meta-analysis.

The systematic methodology of this review was based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement [23].

### **Results**

### Study selection

The literature search identified 672 studies. After an initial screening of the titles, 453 studies were excluded. Another 142 articles were excluded after reading the abstracts and 48 articles were excluded after reading the full-text because they did not meet the eligibility criteria. An additional 14 articles were included after identifying them from the reference lists of the already included papers. A total of 43 articles were included in the qualitative systematic review (Fig. 1).

# **ESBL-producing Enterobacteriaceae**

We included 18 articles: 13 observational studies [24–36] and 5 randomized studies [37–41] (Table 1). Clinical success and mortality by antibiotics are presented in Figs. 2 and 3. Four studies compared treatment with group 1 carbapenems (ertapenem) to treatment with group 2 carbapenems (imipenem/meropenem) [25, 32, 36, 38]. No difference was found in clinical and microbiological success [38], but conflicting results were reported for mortality [32, 36, 38].

Table 3 Choice of treatment and outcome for Pseudomonas aeruginosa


	Pseudomonas aeruginosa															
Study characteristics														Study quality		
Source	Study type	Publication year and country of origin	Study period	Setting	Inclusion criteria	No. of patients (incl/all)	Mean age (years)	Antimicrobial treatment	Route	Follow- up	Site of infection	Outcomes evaluated	Outcome measures	Results	Factors reported as being adjusted for	Quality assessment
Sorli et al	Prospective observational cohort study	2017, Spain	2009- 2013	Н	All patients with microbiologically documented infections due to XDR P. acruginosa and were administered colistin for at least 72 hours	91	Age range: 24-88	Colistin	IV	Until discharge or death	Any	Clinical success 30-day all- cause mortality	Absolute value	Clinical success 79% 30-day all-cause mortality 31%	Male sex, age, APACHE score, Comorbidities, Charlson score, McCabe score, severe sepsis, department of hospitalization, CMS daily dose CSs (mg/mL), CSs > 1.25 (mg/mL), CSs/MIC, AKI at day 7, AKI at the EOT, Length of stay	Fair
Wright et al	Randomised, double-blind, placebe- controlled phase I/II clinical trial	2009, United Kingdom	NR	ОС	Longstanding, antibiotic resistant, aural discharge due to infection exclusively or predominantly by <i>P.</i> acringtness;	24	56.7	Biophage-PA or placebo	Injection into one ear	Day 7, 21 and 42	Ear	Physician reported VAS Patient reported VAS Pseudomonas count	Mean reduction as percentage of day 0	Mean combined VAS Biophage-PA: 50% reduction Placebe: 20% reduction Pseudomonas count Biophage PA day 7: 57% day 21: 17% [p-0.001] day 42: 24% [p-0.016] Placebo day 7: 142% (p day 21: 79% day 21: 79% day 42: 109%	None	Fair
Montero et al	Retrospective observational study	2009, Spain	1997- 2006	Н	Patients who received treatment with collistin for more than 3 days following an episode of active infection with MDR P. aeruginosa	121	65.34 (± 14.1)	Colistin or colistin associated with aminoglycosides, β-lactams, quinolones or carbapenems	IV and IV+Nb	NR	Any	Clinical success	Absolute value	Clinical success C: 73% C+aminoglycosides 72% C+β-lactam 72% C+quinolones 75% C+carbapenem 66%	Site of infection, hypertension, chronic renal insufficiency, diabetes mellitus, Aminoglycosides, ACE-inhibitors	Poor
Carmeli et al*	Randomized phase III study	2016, Worldwide including 16 countries	2013- 2014	Н	Patients aged 18-90 years with onegoin symptoms of either complicated UTI or pyelonephritis or clAff at the time of screening and an isolarded causative Gran-nigatif can be the complete of the complete of previous annibiotic therapy. Patients who had received previous antibacterial agents that were effective in vitro against the isolated pathogen (based on the known susceptibility profile of the organism) were required to have worsening of objective symptoms or signs of infection after 48 h or longer of therapy, or absence of improvement after 72 hours or longer of therapy.	21/333	64.3 (± 14.6) and 61.3 (±15.3) and 49.9 (±16.1) and 68.4 (±11.1)	CA or BAT	IV	TOC visit 7-10 days after last infusion of treatment therapy	UTI	Clinical success Microbiological success	Absolute value	Clinical success in UTI CA: 80% BAT: 100% BAT: 100% Microbiological success in UTI CA: 79% BA: 60% Clinical success in clal CA: 100% Microbiological success in clAl BA: 100% CA: 100% CA: 100%	None	Fair

Abbreviations: No. = number, incl = included patients with relevant infection, H = hospital setting. OC = outpatient clinic, XDR = extended drug resistant, CA = ceftazidime-avibactam, BAT = Best available treatment, IV = intravenous, Nb = nebulized, NR = not reported, TOC = test-of-cure, UTI = nine tract infection, CAI = complicated intra abdominal infection, VAS = visual analogue scale, C = colistin, APACHE = Acute Physiology And Chronic Health Evaluation II, CMS = colistimethate sodium, Css = colistin steady state, MIC = minimal infinitory concentration, AKI = acute kidney injury, ECD = end of treatment are including treatment and outcome for more than one bacteria therefore mentioned in more tables, but only included once in the study. Grayscale = Studies comparing treatment on folios:

Lee et al. reported a lower sepsis-related mortality among 251 patients receiving appropriate therapy (11%) compared to those receiving inappropriate therapy (38%) regardless of whether it was ertapenem, imipenem, or meropenem [33]. Bassetti et al. showed that treating ventilator-associated pneumonia with ertapenem had more than 75% clinical and microbiological success [42]. No difference was found in 30-day mortality for treatment with fluoroquinolones compared to carbapenems, whereas patients treated with cefepime were more likely to die within 30 days than patients treated with carbapenems [34]. A single study [24]


found no difference between ertapenem and piperacillintazobactam in mortality or microbiological success for patients with acute pyelonephritis.

Goetheart et al. compared imipenem/meropenem as monotherapy or in combination with other antibiotic treatment options to treatment with cefepime [27]. Patients treated with cefepime and imipenem/meropenem had similar clinical and microbiological success and 30day mortality. Solomkin et al. found no difference in clinical success between ceftolozane/tazobactam+metronidazole and meropenem treatment [40]. Carmeli et al.




investigated ceftazidime-avibactam against group 2 carbapenem monotherapy (mostly imipenem and meropenem, but also other treatments) [41] in 263 patients with urinary tract infection and 20 patients with complicated intraabdominal infections (cIAIs) caused by ESBL-producing Enterobacteriaceae or P. aeruginosa. Clinical success was reported in more than 92% of patients with urinary tract infection caused by ESBL-producing Enterobacteriaceae treated with ceftazidime-avibactam and best available treatment (monotherapy with amikacin, colistin, doripenem, ertapenem, ertapenem sodium, gentamicin, imipenem, or meropenem piperacillin/tazobactam and combination therapy with ciprofloxacin + meropenem or colistin + imipenem), whereas microbiological success was achieved in 64% of patients treated with ceftazidime-avibactam compared to 82% treated with best available treatment. Clinical success was reported in 5 of 11 patients with cIAI due to ESBLproducing Enterobacteriaceae treated with ceftazidimeavibactam compared to 8 of 9 patients treated with the best available treatment.

treatment options included tazobactam vs. ertapenem vs. cefepime [37], ceftolozane/ tazobactam vs. levofloxacin and ceftolozane/tazobactam vs. ertapenem [39], and ceftazidime vs. imipenem/cilastatin vs. cefoperazone/sulbactam [29]. Seo et al. reported a difference in clinical success when treating 72 patients with urinary tract infection with piperacillin-tazobactam vs. ertapenem vs. cefepime (94% vs. 97% vs. 33%), whereas microbiological success and 28-day mortality were similar [37]. A phase III clinical trial [39] investigated patients with urinary tract infection randomly assigned to treatment with ceftolozane-tazobactam or levofloxacin, and patients with cIAI randomly assigned to treatment with ceftolozanetazobactam or ertapenem. Better clinical success was noted when treating urinary tract infection with ceftolozane/tazobactam compared to levofloxacin (98 and 83%). The clinical success in patients with cIAI was 96% for ceftolozane/ tazobactam and 89% for carbapenem. Bin et al. found similar clinical success when treating with ceftazidime imipenem/cilastatin and cefoperazone/sulbactam [29].



In conclusion, for ESBL-producing Enterobacteriaceae, treatment with carbapenems (ertapenem and meropenem) was associated with low sepsis-related mortality [33]. Seven studies found similar effects between a number of alternative treatment options and carbapenems regarding mortality [24, 27, 35, 37], clinical success [27, 40, 41, 43], and microbiological success [27, 43]. Regarding the clinical success, the following drugs alone or in

combination had a success rate > 90%: piperacillintazobactam, ceftolazane-tazobactam, ertapenem, ertapenem, cefoxitin, ceftolozane-tazobactam in addition to metronidazole, amikacin, and cetazidime-avibactam. In addition, the following drugs had 80 to 90% clinical success: levofloxacin, ceftazidime, imipenem-cilastatin, and meropenem. Mortality was less than 10% for piperacillin-tazobactam and fluoroquinolones. However,



more than 10% mortality was observed for cefepime, imipenem/meropenem, and carbapenem. Conflicting results regarding mortality were observed for ertapenem.

### Acinetobacter baumannii

We identified 22 studies, 16 of which were observational studies [44–59], five were randomized clinical trials [60–64], and one was systematic review and meta-analysis [65] (Table 2). The studies were based on populations with different sites of infection (airways, bloodstream, abdomen, skin, and meninges) and study population size varying from 10 to 250 patients.

Four articles compared colistin monotherapy to colistin combination therapy. Yilmaz et al. reported 77% clinical success with colistin monotherapy compared to 64 and 55% for colistin-carbapenem therapy and colistin-sulbactam therapy, respectively [46]. Sirijatupha et al. reported 63% clinical success with colistin monotherapy and 56% for colistin-fosfomycin combination therapy [60]. Batirel et al. reported a clinical success rate of 31% for monotherapy and 46% for colistin combination therapy (carbapenem, sulbactam, and other agents) [48]. Finally, Aydemir et al. reported 52% clinical success with colistin monotherapy compared to 41% with colistin-rifampicin [61].

Conflicting results have been reported regarding the microbiological success of colistin monotherapy compared to combination therapy with carbapenem or sulbactam. Two studies found no difference in microbiological success [46, 61], whereas Batirel et al. found that combination therapy for bloodstream infection had a better microbiological outcome than monotherapy [48]. Durante-Mangoni et al. found that microbiological success was more likely with colistin-rifampicin combination therapy than colistin monotherapy [64]. Systemic colistin and combinations with localized colistin have been shown to have similar effects on mortality [59].


Therapy with ampicillin-sulbactam was not superior to colistin monotherapy with regard to clinical success, 14day mortality, or 28-day all-cause mortality among patients with MDR A. baumannii ventilator-associated pneumonia [62]. Betrosian et al. found similar clinical success and 30-day mortality when comparing low and high doses of ampicillin-sulbactam among patients with ventilator-associated pneumonia, but microbiological success was better in the low dose group [63]. Colistinfosfomycin combination therapy had better microbiological success than colistin monotherapy, whereas 28day all-cause mortality was similar when MDR A. baumannii infection at various sites was treated [60]. Tigecycline therapy was not superior to colistin therapy in terms of microbiological and clinical success or 30-day mortality among critically ill patients with MDR A. bau*mannii* pneumonia [52, 58]. In another study, combination therapy with colistin-tigecycline and colistin-carbapenem resulted in 14-day all-cause mortality of 35% vs. 15% and all-cause in-hospital mortality of 69% vs. 50%, respectively [54]. Kengkla et al. reported similar clinical success when comparing different colistin combination therapies to different colistin monotherapies, but a better microbiological outcome was demonstrated with colistin combination therapy vs. colistin monotherapy, and tigecycline combination therapy vs. tigecycline monotherapy [65]. No difference was found in all-cause mortality between colistin combination therapy vs. sulbactam combination therapy [65]. Antibiotics other than colistin were evaluated in several small studies [49–51, 53, 57].

In conclusion, for *A. baumannii*, colistin combination therapy had no clear advantage over colistin monotherapy in regards to clinical success [46, 48, 60, 61] (Fig. 4). However, conflicting results have been reported regarding microbiological success when evaluating colistin monotherapy and colistin in combination with carbapenem [46], sulbactam [48], or rifampicin [61, 64]. Therapy with colistin monotherapy did not have a better outcome than ampicillin/sulbactam [52], and no difference in mortality was reported for any treatment comparison. Furthermore, tigecycline and minocycline [49, 51, 58] had a good effect on clinical and microbiological outcome, but the studies were small.

# Pseudomonas aeruginosa

Four studies on *P. aeruginosa* were included in our review: two observational studies [66, 67] and two randomized controlled studies [41, 68] (Table 3). The largest study population comprised 263 patients. Clinical success rates are presented in Fig. 5.

Sorli et al. reported a clinical success rate of 79% after 30-days and a 30-day mortality of 31% for treatment with intravenous colistimethate sodium for P. aeruginosa infection at any site, except acute bronchitis and tracheitis [66]. Montero et al. reported similar clinical success for treatment with colistin monotherapy versus colistin combination therapy (aminoglycosides, β-lactams, quinolones, and carbapenems) in patients infected with P. aeruginosa at different infection sites [67]. Carmeli et al. compared ceftazidime-avibactam to the best available treatment (monotherapy with amikacin, colistin, doripeertapenem, ertapenem sodium, gentamicin, imipenem, meropenem or piperacillin/tazobactam and combination therapy with ciprofloxacin + meropenem or colistin + imipenem) for patients with urinary tract infection or cIAI caused by MDR P. aeruginosa or ESBL-producing Enterobacteriaceae. Clinical and microbiological success occurred in 86 and 79% of patients with P. aeruginosa-specific urinary tract infection treated




with ceftazidime-avibactam and 100% of patients treated with the best available treatment [41].

In conclusion, for *P. aeruginosa*, evaluated studies were characterized by heterogeneous study design, site of infection, and treatment used. Clinical success between 70 and 100% was reported regardless of the type of antibiotic treatment (Fig. 5). A high clinical success rate of up to 100% for ceftazidime-avibactam was demonstrated in the randomized study of Carmeli et al., in which a number of exclusion criteria were applied (i.e., both patients with complicated urinary tract infection and

intra-abdominal infection were excluded, as were patients with evidence of abnormal liver function). Due to small sample sizes and variability in the type of antibiotics used, it is not possible to recommend one specific antibiotic over another.

### Risk of Bias

In general, the study quality varied, 16% (n = 7) of studies were poor in terms of quality, 74% (n = 32) were fair, and only 9% (n = 4) were good quality (Tables 1, 2 and 3).



### Discussion

In summary, we identified 43 articles that report on the clinical success, microbiological success, and/or mortality of different treatment options for the three most common MDR Gram-negative bacteria: ESBL-producing Enterobacteriaceae, A. baumannii, and P. aeruginosa. A variety of antimicrobial regimens have been used, but we did not find robust evidence that would lead to a firm recommendation of one specific antibiotic over another or for monotherapy over combination therapy with regard to efficacy in infections caused by these three different groups of MDR bacterial species. For the treatment of ESBLproducing Enterobacteriaceae, the most commonly used antibiotics were carbapenems. The effect of group 1 carbapenems (ertapenem) compared to group 2 carbapenems (imipenem, meropenem or doripenem) was heterogeneous with regard to reducing mortality, whereas the clinical and microbiological success were similar for group 1 and 2 carbapenems and other non-carbapenem antibiotics. Carbapenem should be used as a 'last-line' antibiotic, and other antibiotics should be used based on the antibiotic resistance profile. For treatment of MDR A. baumannii, intravenous colistin was used as the first drug of choice. Clinical success and mortality were similar in cases treated with colistin combination therapy or monotherapy, whereas heterogeneous results were found with regard to microbiological success. One study compared ampicillin/sulbactam to colistin monotherapy and found that patient groups had a similar outcome. The most common option for treatment of MDR P. aeruginosa infections was intravenous colistin, regardless of infection site.

Adverse reactions to the antibiotics were not a focus of this study but are an important aspect in the treatment of patients, as dosage adjustments must be considered and may have affected the results in this review in terms of clinical success, bacteriological success, and mortality. Another perspective is that patients infected with the studied bacteria are often critically ill, which makes it important to have extensive knowledge of the effects and side effects of the treatment of choice (e.g., the occurrence of nephrotoxicity due to colistin treatment makes colistin a less favorable choice than other antibiotics). Antimicrobial therapy can contribute to curation, but in many complicated infections, surgery and drainage procedures are essential. The included studies that reported multivariate analyses often emphasized the confounding effects of the severity of illness and patient comorbidity.

Ceftazidime-avibactam was introduced in the USA in 2015 and on the European market in 2016 for treatment of adults with complicated urinary tract infections, complicated intra-abdominal infections, hospital-acquired pneumonia, and other infections caused by Gramnegative organisms in patients with limited treatment

options [69]. Current evidence of the effectiveness of ceftazidime-avibactam compared to treatment with carbapenem monotherapy in patients with ceftazidime-resistant Enterobacteriaceae and *P. aeruginosa* is good, and combinations could be considered to reduce the occurrence of carbapenem-resistant bacteria.

To the best of our knowledge, no other systematic reviews have resulted in specific guidelines for treatment of MDR Gram-negative infections. A prior systematic review suggested that colistin combination therapy may be preferred to colistin monotherapy for severely ill patients infected with MDR A. baumannii, but no firm evidence could be found [19]. Another systematic review proposed treating carbapenem-resistant ESBL-producing Enterobacteriaceae and P. aeruginosa with carbapenem plus either colistin or tigecycline combination therapy in low-level resistant infections and colistin-tigecycline combination therapy in high-level resistant infections [18]. Similar findings were published by Rafailidis et al. in 2014, concluding that carbapenem in combination with colistin or high-dose tigecycline or aminoglycosides could be used for treatment of carbapenem-resistant ESBL-producing Enterobacteriaceae in cases in which the minimum inhibitory concentration ranges of carbapenems are  $\leq 8 \text{ mg/L } [20]$ .

The included studies were heterogeneous in terms of study design, patient population, site of infection, choice of antibiotic treatment, duration of follow-up, and outcome definitions, making it difficult to compare the different treatments and combinations of antibiotics used. Subsequently, we were not able to pool results for a meta-analysis. Most patients included in the studies were critically ill, with multiple comorbidities, and admitted to an intensive care unit; these factors may lead to underestimating the specific effect of a certain antibiotic treatment on mortality. Some studies included patients regardless of the site of infection, whereas other studies included patients with specific infections, such as pneumonia or urinary tract infection. The severity of these infections is different, which again can affect the antibiotic treatment-related outcome. In addition, the studies were often based on small sample sizes, reducing the ability to find any effect difference and to consider confounder adjustment and multivariate regression analysis. Only a few studies [24, 25, 34, 36, 40, 44, 47, 51, 52, 54, 55, 64] presented a sample size estimation and adhered

Our study has several limitations. We only used the MEDLINE database for the literature search, which may not cover all published articles. We limited our search to the English, German, and French languages. As countries speaking other languages may have greater problems with MDR bacteria, we may have missed articles published in other languages. However, due to the major

shift towards the publication of studies in English, the extent and effects of language bias may have decreased over the last few years. Lack of a standard definition of MDR results in a great diversity of published papers when defining MDR [70]. Consequently, the use of the term MDR in our search strategy may not cover the same bacteria and drug resistance, and we may have missed some relevant articles. In an attempt to avoid excluding relevant literature, different synonyms were accepted as MDR (e.g., carbapenem resistance and XDR) and all references in the included articles were screened for eligibility. Our inclusion criteria did not take susceptibility profile testing into consideration. Therefore, our results do not differentiate between studies with adequate and inadequate empiric treatment based on the susceptibility profile and studies in which treatment was targeted after the microbiological results were available. However, the vast majority of studies did not clearly state whether the susceptibility profile testing was done before the initiation of treatment. Risk of publication bias is another limitation of this review. It is possible that studies reporting on antibiotic treatment with high clinical and microbiological success rates are more likely to be published. Approximately 50% of the studies are estimated to be unpublished, including a majority of studies with less significant or negative results. Furthermore, 36% of the included studies were found by screening the reference lists of published articles, which may have caused notation bias.

### **Conclusions**

A variety of antimicrobial therapies have been used for treatment of the three most common MDR Gramnegative bacteria: ESBL-producing Enterobacteriaceae, A. baumannii, and P. aeruginosa. Carbapenems, in many situations, may have similar clinical and microbiological success rates as other antimicrobial regimens when used for the treatment of infections caused by ESBLproducing Enterobacteriaceae. For treatment of MDR A. baumannii, clinical success and mortality were similar in cases treated with colistin combination therapy compared to monotherapy, as well as in several studies comparing colistin with other antibiotics. The most common choice for treatment of MDR P. aeruginosa infections was intravenous colistin, regardless of infection site. Other antibiotic therapies had a similar effect as colistin, but due to small sample sizes and variability in the type of antibiotics used, it is not possible to recommend one specific antimicrobial regimen over another. The choice of definite antibiotic treatment should be based on susceptibility testing balancing the expected clinical success rate against the risk of development of antibiotic resistance and the risk of severe side effects. Taking into account the absence of evidence and all considerations above, for now, a personalized medicine approach and involvement of specialists in infectious diseases and microbiology are key measures to provide optimal treatment for each patient affected by infection caused by MDR microorganisms.

# Supplementary information

Supplementary information accompanies this paper at https://doi.org/10. 1186/s13756-019-0624-1

Additional file 1. PICOS criteria.

Additional file 2. Search criteria

### Abbreviations

cIAI: Complicated intra-abdominal infection; ESBL: Extended-spectrum beta-lactamase; HR: Hazard ratio; MDR: Multidrug-resistant

### Acknowledgements

Not applicable

### Authors' contributions

SMN, CSJ, and JA designed the work, acquired data, interpreted the data, drafted the work, modified and approved the submitted version, and are responsible for the manuscript. MB and CV interpreted data, substantively revised the work, approved the submitted version, and agreed to be personally accountable for the author's own contributions. ABP designed the work, interpreted data, substantively revised the work, approved the submitted version, is responsible for the manuscript, and agreed to be personally accountable for the author's own contributions.

### Funding

The research received a specific grant from the European Medicines Agency (EMA) contract EMA/2015/24/PH. The EMA has commented on the review content but did not have a final decision on the interpretations or conclusions of the review.

### Availability of data and materials

The datasets generated during the current study are available from the corresponding author upon reasonable request.

### Ethics approval and consent to participate

Not applicable

### Consent for publication

Not applicable

# Competing interests

The authors declare that they have no competing interests.

### Author details

<sup>1</sup>Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Allé 43-45, 8200 Aarhus, N, Denmark. <sup>2</sup>Department of Infectious Diseases, Leiden University Medical Center, Albinusdreef 2, 2333, ZA, Leiden, The Netherlands. <sup>3</sup>Medical Microbiology and Infection Control, Amsterdam University Medical Centers, Vrije Universiteit, De Boelelaan 1117 Amsterdam, 1081, HV, Amsterdam, The Netherlands.

Received: 17 June 2019 Accepted: 9 October 2019 Published online: 04 November 2019

### References

- WHO. Antimicrobial resistance: global report on surveillance. 2015. Available on: https://apps.who.int/iris/bitstream/handle/10665/112642/978924156474 8\_eng.pdf;jsessionid=6340DE5721019788DC15BBF4EAD4B8F6?sequence=1. Accessed 26 Oct 2019.
- Giske CG, Monnet DL, Cars O, Carmeli Y. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother. 2008;52(3):813–21.

- Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P t. 2015;40(4):277–83.
- Antimicrobial resistance surveillance in Europe Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2014. Stockholm: ECDC; 2015. Available on: https://www.ecdc.europa.eu/sites/ default/files/media/en/publications/Publications/antimicrobial-resistanceeurope-2014.pdf.
- Taneja N, Kaur H. Insights into newer antimicrobial agents against gramnegative Bacteria. Microbiol Insights. 2016;9:9–19.
- Rossolini GM, Arena F, Pecile P, Pollini S. Update on the antibiotic resistance crisis. Curr Opin Pharmacol. 2014;18:56–60.
- Ramphal R, Ambrose PG. Extended-spectrum beta-lactamases and clinical outcomes: current data. Clin Infect Dis. 2006;42(Suppl 4):S164–72.
- Chopra T, Marchaim D, Veltman J, Johnson P, Zhao JJ, Tansek R, Hatahet D, Chaudhry K, Pogue JM, Rahbar H, Chen TY, Truong T, Rodriguez V, Ellsworth J, Bernabela L, Bhargava A, Yousuf A, Alangaden G, Kaye KS. Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother. 2012; 56(7):3936–42
- Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol. 2007; 5(12):939–51.
- Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect Dis. 2006;6(9):589–601.
- Lee CS, Doi Y. Therapy of infections due to Carbapenem-resistant gramnegative pathogens. Infect Chemother. 2014;46(3):149–64.
- Cassini A, Hogberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, Colomb-Cotinat M, Kretzschmar ME, Devleesschauwer B, Cecchini M, Ouakrim DA, Oliveira TC, Struelens MJ, Suetens C, Monnet DL. Attributable deaths and disability-adjusted life-years caused by infections with antibioticresistant bacteria in the EU and the European economic area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56–66.
- Gandra S, Barter DM, Laxminarayan R. Economic burden of antibiotic resistance: how much do we really know? Clin Microbiol Infect. 2014; 20(10):973–80.
- David N. Gilbert, H.F.C., George M. Epiopoulos, Michael S. Saag, Andrew T. Pavia, Douglas Black, David O Freedman, Kami Kim, Brian S. Schwartz, The Sanford guide. To Antimicrobial therapy 2017. 47th ed. 2017.
- Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1–12.
- Livermore DM, Warner M, Mushtaq S, Doumith M, Zhang J, Woodford N. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents. 2011;37(5):415–9.
- 17. Giamarellou H, Poulakou G. Multidrug-resistant gram-negative infections: what are the treatment options? Drugs. 2009;69(14):1879–901.
- Izadpanah M, Khalili H. Antibiotic regimens for treatment of infections due to multidrug-resistant gram-negative pathogens: an evidence-based literature review. J Res Pharm Pract. 2015;4(3):105–14.
- Poulikakos P, Tansarli GS, Falagas ME. Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review. Eur J Clin Microbiol Infect Dis. 2014;33(10):1675–85.
- 20. Rafailidis Pl, Falagas ME. Options for treating carbapenem-resistant Enterobacteriaceae. Curr Opin Infect Dis. 2014;27(6):479–83.
- Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. Multidrugresistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–81.
- The National Heart, Lung, and Blood Institute. Guidance for Quality
   Assessment Tool for Systematic Reviews and Meta-Analyses. Available from:
   https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools.

   Accessed 5 Aug 2018.
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.

- Yoon YK, Kim JH, Sohn JW, Yang KS, Kim MJ. Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum beta-lactamase-producing Escherichia coli. Int J Antimicrob Agents. 2017;49(4):410–5.
- Gutierrez-Gutierrez B, Bonomo RA, Carmeli Y, Paterson DL, Almirante B, Martinez-Martinez L, Oliver A, Calbo E, Pena C, Akova M, Pitout J, Origuen J, Pintado V, Garcia-Vazquez E, Gasch O, Hamprecht A, Prim N, Tumbarello M, Bou G, Viale P, Tacconelli E, Almela M, Perez F, Giamarellou H, Cisneros JM, Schwaber MJ, Venditti M, Lowman W, Bermejo J, Hsueh PR, Mora-Rillo M, Gracia-Ahulfinger I, Pascual A, Rodriguez-Bano J. Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. J Antimicrob Chemother. 2016; 71(6):1672–80.
- Bassetti M, Righi E, Fasce R, Molinari MP, Rosso R, Di Biagio A, Mussap M, Pallavicini FB, Viscoli C. Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum betalactamase-producing organisms in an intensive care unit. J Antimicrob Chemother. 2007;60(2):433–5.
- Goethaert K, Van Looveren M, Lammens C, Jansens H, Baraniak A, Gniadkowski M, Van Herck K, Jorens PG, Demey HE, leven M, Bossaert L, Goossens H. High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients. Clin Microbiol Infect. 2006;12(1):56–62.
- Kerneis S, Valade S, Geri G, Compain F, Lavollay M, Rostane H, Carbonnelle E, Mainardi JL. Cefoxitin as a carbapenem-sparing antibiotic for infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infect Dis (Lond). 2015;47(11):789–95.
- Bin C, Hui W, Renyuan Z, Yongzhong N, Xiuli X, Yingchun X, Yuanjue Z, Minjun C. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli. Diagn Microbiol Infect Dis. 2006;56(4):351–7.
- Tasbakan MI, Pullukcu H, Sipahi OR, Yamazhan T, Ulusoy S. Nitrofurantoin in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infection. Int J Antimicrob Agents. 2012; 40(6):554–6.
- 31. Ipekci T, Seyman D, Berk H, Celik O. Clinical and bacteriological efficacy of amikacin in the treatment of lower urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae. J Infect Chemother. 2014;20(12):762–7.
- Lee NY, Huang WH, Tsui KC, Hsueh PR, Ko WC. Carbapenem therapy for bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae. Diagn Microbiol Infect Dis. 2011; 70(1):150–3.
- Lee NY, Lee CC, Huang WH, Tsui KC, Hsueh PR, Ko WC. Carbapenem therapy for bacteremia due to extended-spectrum-beta-lactamaseproducing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility. Antimicrob Agents Chemother. 2012;56(6):2888–93.
- Lee NY, Lee CC, Huang WH, Tsui KC, Hsueh PR, Ko WC. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extendedspectrum beta-lactamase-producing Enterobacteriaceae: MIC matters. Clin Infect Dis. 2013;56(4):488–95.
- Lo CL, Lee CC, Li CW, Li MC, Hsueh PR, Lee NY, Ko WC. Fluoroquinolone therapy for bloodstream infections caused by extended-spectrum betalactamase-producing Escherichia coli and Klebsiella pneumoniae. J Microbiol Immunol Infect. 2015;50(3):355–61.
- Collins VL, Marchaim D, Pogue JM, Moshos J, Bheemreddy S, Sunkara B, Shallal A, Chugh N, Eiseler S, Bhargava P, Blunden C, Lephart PR, Memon BI, Hayakawa K, Abreu-Lanfranco O, Chopra T, Munoz-Price LS, Carmeli Y, Kaye KS. Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2012;56(4):2173–7.
- Seo YB, Lee J, Kim YK, Lee SS, Lee JA, Kim HY, Uh Y, Kim HS, Song W. Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extendedspectrum beta-lactamase-producing Escherichia coli. BMC Infect Dis. 2017; 17(1):404.
- Rattanaumpawan P, Werarak P, Jitmuang A, Kiratisin P, Thamlikitkul V. Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: an open-label randomized controlled trial. BMC Infect Dis. 2017;17(1):183.

- Popejoy MW, Paterson DL, Cloutier D, Huntington JA, Miller B, Bliss CA, Steenbergen JN, Hershberger E, Umeh O, Kaye KS. Efficacy of ceftolozane/ tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of phase 3 clinical trials. J Antimicrob Chemother. 2017;72(1):268–72.
- Solomkin J, Hershberger E, Miller B, Popejoy M, Friedland I, Steenbergen J, Yoon M, Collins S, Yuan G, Barie PS, Eckmann C. Ceftolozane/Tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis. 2015;60(10):1462–71.
- Carmeli Y, Armstrong J, Laud PJ, Newell P, Stone G, Wardman A, Gasink LB. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016;16(6):661–73.
- Bassetti M, Repetto E, Righi E, Boni S, Diverio M, Molinari MP, Mussap M, Artioli S, Ansaldi F, Durando P, Orengo G, Bobbio Pallavicini F, Viscoli C. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother. 2008;61(2):417–20.
- Park SH, Choi SM, Chang YK, Lee DG, Cho SY, Lee HJ, Choi JH, Yoo JH. The
  efficacy of non-carbapenem antibiotics for the treatment of communityonset acute pyelonephritis due to extended-spectrum beta-lactamaseproducing Escherichia coli. J Antimicrob Chemother. 2014;69(10):2848–56.
- 44. Alvarez-Marin R, Lopez-Rojas R, Marquez JA, Gomez MJ, Molina J, Cisneros JM, Ortiz-Leyba C, Aznar J, Garnacho-Montero J, Pachon J. Colistin dosage without loading dose is efficacious when treating Carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia caused by strains with high susceptibility to Colistin. PLoS One. 2016;11(12):e0168468.
- Bremmer DN, Bauer KA, Pouch SM, Thomas K, Smith D, Goff DA, Pancholi P, Balada-Llasat JM. Correlation of checkerboard synergy testing with time-kill analysis and clinical outcomes of extensively drug-resistant Acinetobacter baumannii respiratory infections. Antimicrob Agents Chemother. 2016; 60(11):6892–5.
- Yilmaz GR, Guven T, Guner R, Kocak Tufan Z, Izdes S, Tasyaran MA, Acikgoz ZC. Colistin alone or combined with sulbactam or carbapenem against a. baumannii in ventilator-associated pneumonia. J Infect Dev Ctries. 2015;9(5):476–85.
- Lopez-Cortes LE, Cisneros JM, Fernandez-Cuenca F, Bou G, Tomas M, Garnacho-Montero J, Pascual A, Martinez-Martinez L, Vila J, Pachon J, Rodriguez Bano J. Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort. J Antimicrob Chemother. 2014;69(11):3119–26.
- 48. Batirel A, Balkan II, Karabay O, Agalar C, Akalin S, Alici O, Alp E, Altay FA, Altin N, Arslan F, Aslan T, Bekiroglu N, Cesur S, Celik AD, Dogan M, Durdu B, Duygu F, Engin A, Engin DO, Gonen I, Guclu E, Guven T, Hatipoglu CA, Hosoglu S, Karahocagil MK, Kilic AU, Ormen B, Ozdemir D, Ozer S, Oztoprak N, Sezak N, Turhan V, Turker N, Yilmaz H. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis. 2014;33(8):1311–22.
- 49. Vasilev K, Reshedko G, Orasan R, Sanchez M, Teras J, Babinchak T, Dukart G, Cooper A, Dartois N, Gandjini H, Orrico R, Ellis-Grosse E. A phase 3, openlabel, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother. 2008;62(Suppl 1):i29–40.
- Saballs M, Pujol M, Tubau F, Pena C, Montero A, Dominguez MA, Gudiol F, Ariza J. Rifampicin/imipenem combination in the treatment of carbapenemresistant Acinetobacter baumannii infections. J Antimicrob Chemother. 2006;58(3):697–700.
- Ye JJ, Lin HS, Kuo AJ, Leu HS, Chiang PC, Huang CT, Lee MH. The clinical implication and prognostic predictors of tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii. J Inf Secur. 2011;63(5):351–61.
- Kim WY, Moon JY, Huh JW, Choi SH, Lim CM, Koh Y, Chong YP, Hong SB. Comparable efficacy of Tigecycline versus Colistin therapy for multidrugresistant and extensively drug-resistant Acinetobacter baumannii pneumonia in critically ill patients. PLoS One. 2016;11(3):e0150642.
- Goff DA, Bauer KA, Mangino JE. Bad bugs need old drugs: a stewardship program's evaluation of minocycline for multidrug-resistant Acinetobacter baumannii infections. Clin Infect Dis. 2014;59(Suppl 6):S381–7.

- Cheng A, Chuang YC, Sun HY, Sheng WH, Yang CJ, Liao CH, Hsueh PR, Yang JL, Shen NJ, Wang JT, Hung CC, Chen YC, Chang SC. Excess mortality associated with Colistin-Tigecycline compared with Colistin-Carbapenem combination therapy for extensively drug-resistant Acinetobacter baumannii bacteremia: a multicenter prospective observational study. Crit Care Med. 2015;43(6):1194–204.
- Kwon KH, Oh JY, Yoon YS, Jeong YJ, Kim KS, Shin SJ, Chung JW, Huh HJ, Chae SL, Park SY. Colistin treatment in carbapenem-resistant Acinetobacter baumannii pneumonia patients: incidence of nephrotoxicity and outcomes. Int J Antimicrob Agents. 2015;45(6):605–9.
- Michalopoulos A, Fotakis D, Virtzili S, Vletsas C, Raftopoulou S, Mastora Z, Falagas ME. Aerosolized colistin as adjunctive treatment of ventilatorassociated pneumonia due to multidrug-resistant gram-negative bacteria: a prospective study. Respir Med. 2008;102(3):407–12.
- Motaouakkil S, Charra B, Hachimi A, Nejmi H, Benslama A, Elmdaghri N, Belabbes H, Benbachir M. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Inf Secur. 2006;53(4):274–8.
- Qin Y, Zhang J, Wu L, Zhang D, Fu L, Xue X. Comparison of the treatment efficacy between tigecycline plus high-dose cefoperazone-sulbactam and tigecycline monotherapy against ventilator-associated pneumonia caused by extensively drug-resistant Acinetobacter baumannii. Int J Clin Pharmacol Ther. 2018;56(3):120–9.
- Chusri S, Sakarunchai I, Kositpantawong N, Panthuwong S, Santimaleeworagun W, Pattharachayakul S, Singkhamanan K, Doi Y. Outcomes of adjunctive therapy with intrathecal or intraventricular administration of colistin for postneurosurgical meningitis and ventriculitis due to carbapenem-resistant acinetobacter baumannii. Int J Antimicrob Agents. 2018;51(4):646–50.
- Sirijatuphat R, Thamlikitkul V. Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother. 2014;58(9):5598–601.
- 61. Aydemir H, Akduman D, Piskin N, Comert F, Horuz E, Terzi A, Kokturk F, Ornek T, Celebi G. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect. 2013;141(6):1214–22.
- Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilatorassociated pneumonia. J Inf Secur. 2008;56(6):432–6.
- Betrosian AP, Frantzeskaki F, Xanthaki A, Georgiadis G. High-dose ampicillinsulbactam as an alternative treatment of late-onset VAP from multidrugresistant Acinetobacter baumannii. Scand J Infect Dis. 2007;39(1):38–43.
- 64. Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, Bassetti M, Malacarne P, Petrosillo N, Galdieri N, Mocavero P, Corcione A, Viscoli C, Zarrilli R, Gallo C, Utili R. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013;57(3):349–58.
- 65. Kengkla K, Kongpakwattana K, Saokaew S, Apisarnthanarak A, Chaiyakunapruk N. Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis. J Antimicrob Chemother. 2018;73(1):22–32.
- Sorli L, Luque S, Segura C, Campillo N, Montero M, Esteve E, Herrera S, Benito N, Alvarez-Lerma F, Grau S, Horcajada JP. Impact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drugresistant Pseudomonas aeruginosa. BMC Infect Dis. 2017;17(1):11.
- Montero M, Horcajada JP, Sorli L, Alvarez-Lerma F, Grau S, Riu M, Sala M, Knobel H. Effectiveness and safety of colistin for the treatment of multidrugresistant Pseudomonas aeruginosa infections. Infection. 2009;37(5):461–5.
- 68. Wright A, Hawkins CH, Anggard EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol. 2009;34(4):349–57.
- Shirley M. Ceftazidime-Avibactam: a review in the treatment of serious gram-negative bacterial infections. Drugs. 2018;78(6):675–92.
- Falagas ME, Rafailidis PI, Kasiakou SK, Hatzopoulou P, Michalopoulos A. Effectiveness and nephrotoxicity of colistin monotherapy vs. colistinmeropenem combination therapy for multidrug-resistant gram-negative bacterial infections. Clin Microbiol Infect. 2006;12(12):1227–30.

# **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.